Tags : positive results

Clinical Trials Pharma

Sanofi and Regeneron Report Positive Results of Dupixent (dupilumab) in

Shots: The P-IIIa Dupixent Eosinophilic Esophagitis study involves assessing Dupixent (N=42) (300mg weekly) v/s PBO (N=39) in 81 patients aged 12 years and older with eosinophilic esophagitis (EoE). In addition, enrolling patients for P-IIIb for extended active treatment period to continue in 28wks The P-II study results: met its co-1EPs and 2EPs in DSQ baseline […]Read More

Pharma

Roche to Present Positive Results of Cancer Immunotherapy Programmes at

Shots: Roche is presenting data that includes results assessing Tecentriq + nab-paclitaxel in Breast Cancer (P-III), Alecensa in lung cancer and Tecentriq in lung (P-III) and liver cancers(P-I) Additionally, presenting Entrectinib’s (RXDX-101) positive results from P-II STARTRK-2, P-I STARTRK-1 and P-I ALKA trials for NTRK gene fusion-positive solid tumors and also received BT and PRIME […]Read More

Pharma

Xspray Pharma Reports Positive P-I Trial Results of HyNap-Dasa for

Shots: The P-I BE study involves assessing of PK limitations i.e. Cmax, AUC for Xspray’s leading product HyNap-Dasa formulated vs Sprycel (Dasatinib) The P-I study (N=16) with healthy candidates administrating single dose of each product, demonstrated positive results while confirming the validity of Xspray’s patented formulation technology The results will be helpful in designing of […]Read More